ReviewInternational journal of molecular sciences2020
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Trial
- Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up.Drug safety · 2026Review
- Advanced quantification pipeline reveals new spatial and temporal tumor characteristics in preclinical multiple myeloma.EJNMMI research · 2025Article
- New Developments in Myeloma Treatment and Response Assessment.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Modern imaging techniques for monitoring patients with multiple myeloma.Medicine and pharmacy reports · 2022Review
- Steps towards a Multiple Myeloma Cure?Journal of personalized medicine · 2022Article
- CT-derived relationship between low relative muscle mass and bone damage in patients with multiple myeloma undergoing stem cells transplantation.The British journal of radiology · 2022Article
- Molecular Imaging in Multiple Myeloma-Novel PET Radiotracers Improve Patient Management and Guide Therapy.Frontiers in nuclear medicine · 2022Review
- Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.Skeletal radiology · 2022Review
- Minimal residual disease in multiple myeloma: current status.Biomarker research · 2021Review
- Review
- Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.Journal of personalized medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum markers and bone marrow examination are commonly used for monitoring therapy response in multiple myeloma (MM), but this fails to identify minimal residual disease (MRD), which frequently persists after therapy even in complete response patients, and extra-medullary disease escape. Positron emission tomography with computed tomography using 18F-deoxyglucose (FDG-PET/CT) is the reference imaging technique for therapeutic assessment and MRD detection in MM. To date, all large prospective cohort studies of transplant-eligible newly diagnosed MM patients have shown a strong and independent pejorative prognostic impact of not obtaining complete metabolic response by FDG-PET/CT after therapy, especially before maintenance. The FDG-PET/CT and MRD (evaluated by flow cytometry or next-generation sequencing at 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.